Community-based screening may be one strategy in which to reach such persons; however, the acceptance of HCV testing, when many high-risk individuals may not have access to HCV specific medications, remains unknown.We set out to assess attitudes about HCV screening and knowledge about HCV disease at several community-based testing sites that serve high-risk populations.
For lung and pancreatic cancer, which account for about 35% of cancer deaths, PAP-based screening may be helpful, as no well accepted and cost effective screen for early tumors is available.
Hence, risk-based screening may be misleading and isolation facilities might become rare in future.
Thus, available evidence suggests that sensitivity of a symptom-based screening may be significantly lower than sensitivity of "traditional" radiographic screening.
Community-based screening may be one strategy in which to reach such persons; however, the acceptance of HCV testing, when many high-risk individuals may not have access to HCV specific medications, remains unknown.
This population-based screening may be less effective when addressing individuals who are already covered by regular care, instead of addressing a hidden key population without chlamydia testing experience in regular care.
Moreover, there is evidence that active case finding based on repeated symptom screening may be effective in reducing prevalence of active tuberculosis and tuberculosis transmission in high burden settings [ 27].
Initial screening may be based on timing of applications, age, current employment status, etc".
Similarly, lack of statistical significance for sensitivity estimates based on time since last negative test or rank of screening may be due to the small number of events.
Our base case assumption of a 20% RRR due to screening may be optimistic and is probably closer to 15% [ 29, 31].
This paper highlights a broader issue that decisions about screening may be driven by the availability of diagnostic testing platforms rather than the evidence base.
